We have exciting news to share with you. We have received the second installment of the investment and have begun paying for the ABBIE technology acquisition. ABBIE is a revolutionary non-viral gene-editing platform that can transform genetics and biotechnology.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.